DEXCOM INC

NASDAQ: DXCM (DexCom, Inc.)

Last update: 30 Aug, 3:44AM

69.62

-0.86 (-1.22%)

Market Trend

Short Term Medium Term
Industry Medical Devices (US) Mixed Bearish
Medical Devices (Global) Mixed Bearish
Stock DexCom, Inc. Bearish Bearish

Stockmoo Score

1.4

Similar Stocks

Stock Market Cap DY P/E P/B
DXCM 28 B - 43.24 11.49
PODD 15 B - 38.76 15.08
BRKR 10 B 0.31% 27.22 5.41
TMDX 5 B - - 25.15
AXNX 3 B - - 5.46
IRTC 3 B - - 22.30

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Sector Healthcare
Industry Medical Devices
Investment Style Mid Growth
52 Weeks Range
62.34 (-10%) — 142.00 (103%)
Price Target Range
75.00 (7%) — 145.00 (108%)
High 145.00 (RBC Capital, 108.27%) Buy
Median 95.00 (36.46%)
Low 75.00 (JP Morgan, 7.73%) Hold
75.00 (Morgan Stanley, 7.73%) Hold
Average 99.73 (43.25%)
Total 8 Buy, 3 Hold
Avg. Price @ Call 66.11
Firm Date Target Price Call Price @ Call
Piper Sandler 26 Aug 2024 90.00 (29.27%) Buy 73.67
26 Jul 2024 90.00 (29.27%) Buy 64.00
Stifel 23 Aug 2024 100.00 (43.64%) Buy 74.07
26 Jul 2024 90.00 (29.27%) Buy 64.00
Barclays 29 Jul 2024 113.00 (62.31%) Hold 67.48
BTIG 26 Jul 2024 120.00 (72.36%) Buy 64.00
Canaccord Genuity 26 Jul 2024 89.00 (27.84%) Buy 64.00
23 Jul 2024 145.00 (108.27%) Buy 112.13
JP Morgan 26 Jul 2024 75.00 (7.73%) Hold 64.00
Morgan Stanley 26 Jul 2024 75.00 (7.73%) Hold 64.00
15 Jul 2024 120.00 (72.36%) Hold 113.01
Oppenheimer 26 Jul 2024 115.00 (65.18%) Buy 64.00
RBC Capital 26 Jul 2024 145.00 (108.27%) Buy 64.00
UBS 26 Jul 2024 95.00 (36.46%) Buy 64.00
Wells Fargo 26 Jul 2024 80.00 (14.91%) Buy 64.00
Show more
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
BROWN MICHAEL JON - 69.34 -686 -47,567
Aggregate Net Quantity -686
Aggregate Net Value ($) -47,567
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 69.34
Name Holder Date Type Quantity Price Value ($)
BROWN MICHAEL JON Officer 30 Aug 2024 Automatic sell (-) 686 69.34 47,567
Date Type Details
04 Sep 2024 Announcement Dexcom to Showcase Transformational Impact of Dexcom CGM Technology at the EASD 2024 Conference Symposium
28 Aug 2024 Announcement Dexcom Announces Upcoming Conference Presentation
26 Aug 2024 Announcement Stelo by Dexcom, the First Over-the-Counter Glucose Biosensor in the U.S., Is Now Available
14 Aug 2024 Announcement RAMQ Expands Provincial Coverage to Include Dexcom G7, Bringing the Next-Generation CGM System to More Québec Residents
29 Jul 2024 Announcement Tandem Diabetes Care and Dexcom Announce the t:slim X2 Insulin Pump with Dexcom G7 CGM Compatibility is Authorized for Sale by Health Canada
29 Jul 2024 Announcement DXCM Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
28 Jul 2024 Announcement Kaplan Fox & Kilsheimer LLP is Investigating Possible Securities Law Violations Against DexCom, Inc. (DXCM)
26 Jul 2024 Announcement Kaplan Fox & Kilsheimer LLP is Investigating DexCom, Inc. (DXCM) for Potential Securities Law Violations
25 Jul 2024 Announcement Dexcom Reports Second Quarter 2024 Financial Results, Updates Guidance, and Announces $750 Million Share Repurchase Program
27 Jun 2024 Announcement Dexcom Schedules Second Quarter 2024 Earnings Release and Conference Call for July 25, 2024 at 4:30 p.m. Eastern Time.
20 Jun 2024 Announcement Dexcom Expands AID Partnership Into The Netherlands
20 Jun 2024 Announcement Dexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People With Type 2 Diabetes
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria